TRYNGOLZA® Receives Positive CHMP Opinion for FCS Treatment
In a significant development, the Committee for Medicinal Products for Human Use (CHMP) has expressed a favorable recommendation for TRYNGOLZA® (olezarsen) as a treatment for familial chylomicronemia syndrome (FCS). This recommendation is based on a comprehensive evaluation of Phase 3 Balance results which demonstrated a meaningful reduction in triglyceride levels and a decrease in acute pancreatitis events.
Significant Clinical Findings
The findings from the Balance study have underscored the potential of TRYNGOLZA as a vital adjunct to diet for adult patients diagnosed with genetically confirmed FCS. The study revealed that participants experienced a substantial reduction in triglycerides, supporting the treatment's promise in managing this rare condition. A decision from the European Commission is anticipated by the fourth quarter of 2025, marking an important milestone in the journey towards broader patient access.
Expert Insights from Sobi and Ionis Pharmaceuticals
Lydia Abad-Franch, MD, MBA, who serves as the Head of Research, Development, and Medical Affairs at Sobi, commented on this pivotal moment, stating, "The approval recommendation brings us one step closer toward delivering TRYNGOLZA to people living with FCS in the EU. This is a significant step forward for the FCS community, which frequently faces severe health challenges, including acute pancreatitis. We are hopeful about the final decision from the EC."
Brett P. Monia, Ph.D., the CEO of Ionis Pharmaceuticals, added, "This CHMP opinion aligns with our broader mission to extend the availability of TRYNGOLZA globally, building upon the successful early launch in the United States. The substantial clinical evidence we have gathered thus far emphasizes our commitment to improving the lives of patients affected by FCS."
Understanding Familial Chylomicronemia Syndrome
Familial chylomicronemia syndrome is a distinct genetic condition characterized by extremely high triglyceride levels due to the body's inability to effectively break down fats. This condition affects individuals who may have triglyceride levels exceeding 880 mg/dL, compared to healthy levels below 150 mg/dL. Consequently, individuals with FCS face a heightened risk for life-threatening complications, heightening the urgency for effective treatment options.
What Lies Ahead for TRYNGOLZA®?
The positive CHMP recommendation is a significant advancement in the long road towards the potential launch of TRYNGOLZA in the European market. Sobi, having exclusive commercialization rights in several regions outside the United States, Canada, and China, is strategically positioned to leverage its existing expertise in the rare disease space to ensure a successful introduction of TRYNGOLZA if approved. The company previously managed the distribution of Waylivra, currently the only approved treatment for FCS in the EU, which illustrates Sobi's capacity to effectively handle market launch processes.
Additionally, olezarsen is currently under evaluation for severe hypertriglyceridemia (sHTG), a serious condition defined by extremely high triglyceride levels, as data from the ongoing Phase 3 CORE and CORE2 studies is anticipated soon.
Details of the Balance Study
Executed as a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study, the Balance trial was critical in assessing the safety and efficacy of TRYNGOLZA among FCS patients. The primary outcome was to measure the percent change in fasting triglyceride levels at six months against a placebo control. Secondary outcomes evaluated additional lipid parameter changes and acute pancreatitis event rates throughout the treatment duration. Patients finishing the initial trial could enter an open-label extension where they could continue receiving TRYNGOLZA at a four-week interval.
About TRYNGOLZA®
TRYNGOLZA® (olezarsen) is an innovative RNA-targeted therapy designed to lower the body’s production of apoC-III. This protein, produced in the liver, plays a crucial role in triglyceride metabolism. Currently, TRYNGOLZA is authorized in the United States, and for patients in Europe, this drug may soon provide a new therapeutic avenue for managing FCS, should it gain approval following the recommended assessment.
Frequently Asked Questions
What is TRYNGOLZA® used for?
TRYNGOLZA® is an RNA-targeted medication approved to treat familial chylomicronemia syndrome by lowering triglyceride levels in patients.
Who recommends the approval of TRYNGOLZA® in Europe?
The recommendation comes from the Committee for Medicinal Products for Human Use (CHMP) based on promising clinical trial data.
What is Familial Chylomicronemia Syndrome?
FCS is a rare genetic disorder characterized by extremely high triglyceride levels due to the body's inability to break down fats effectively.
What are the expected outcomes of the Balance study?
The Balance study aims to demonstrate significant reductions in triglyceride levels and lower incidence of acute pancreatitis events over 12 months.
What is the next step for TRYNGOLZA® following the positive CHMP opinion?
The next step is awaiting a decision from the European Commission regarding approval, expected by late 2025.
